Diese Präsentation wurde erfolgreich gemeldet.
Wir verwenden Ihre LinkedIn Profilangaben und Informationen zu Ihren Aktivitäten, um Anzeigen zu personalisieren und Ihnen relevantere Inhalte anzuzeigen. Sie können Ihre Anzeigeneinstellungen jederzeit ändern.

platelet rich plasma in reproductive medicine

1.756 Aufrufe

Veröffentlicht am

Aboubakr Elnashar

Veröffentlicht in: Gesundheit & Medizin
  • Als Erste(r) kommentieren

platelet rich plasma in reproductive medicine

  1. 1. 1/12/2020 1 PLATELET RICH PLASMA (PRP) In Reproductive Medicine: Current Status Prof. Aboubakr Elnashar Benha university Hospital, Egypt ABOUBAKR ELNASHAR INTRODUCTION  PRP  Preparation: simple& easily performed.  Contain high concentrations of 1. Cytokines 2. Growth factors ABOUBAKR ELNASHAR
  2. 2. 1/12/2020 2  Mechanisms of action  High concentration of growth factors: tissue regeneration& healing.  The fibrin framework present over platelets support the regenerative matrix: rapid establishment of the proper morphological and molecular configuration for wound healing ABOUBAKR ELNASHAR Preparation Centrifuge at 1,200 rpm for 12 min  Upper: platelets & WBC  Intermediate thin: rich in WBC  Bottom: RBC Centrifuged at 3,300 rpm for 7 min ABOUBAKR ELNASHAR
  3. 3. 1/12/2020 3  Platelet activation  triggers the release of these growth factors by  thrombin  calcium chloride  collagen.  Each method influences both  physical form of PRP  amount of growth factors released  kinetics of release. ABOUBAKR ELNASHAR OBJECTIVE: To review uses of PRP in reproductive medicine. METHODS  A literature search for English articles, related to uses of PRP in reproductive medicine, including articles published in Pub Med.  From 2000 to october 2019  Keywords: PRP, ICSI, Endometrium, Ovary ABOUBAKR ELNASHAR
  4. 4. 1/12/2020 4 RESULTS  21 studies  Intraovarian: 5 studies  Intrauterine: 16 studies ABOUBAKR ELNASHAR Indication No of patients Type of study 1. Diminished ovarian reserve  Sills et al, 2018, Gynecol Endocrinol. 4 Case series 2. Poor responders  Sfakianoudis et al, 2019, Gynecol Obstet Invest.  Farimani et al, 2019, Mol Biol Rep J 3 19 Case series Case series 3. Premature ovarian failure  Pantos et al., 2019, Cell Transp  Sfakianoudis et al, 2018. J. Clin. Med. 3 1 Case series Case report Total 30 INTRA OVARIAN PRP ABOUBAKR ELNASHAR
  5. 5. 1/12/2020 5 Intra ovarian infusion Procedure  Timing:  At the end of the periods  Minimal sedation  Injection:  under direct TVS guidance  using oocyte pick up needle (17-gauge)  Slowly& steadily. To ensure  Uniform distribution of infusion in all layers  Needle is gently retracted while injecting  3 punctures per ovary, intramedullary injection, and diffusion in the subcortical layers.(Sfakianoudis et al, 2018)  Amount into each ovary  2 mL (Farimani et al, 2019)  4 ml (Pantos et al, 2019)  5 mL (Sills et al, 2018)  After the procedure  supine position for 10–15 min  rest for one hour.  Repeat procedure /month for 2-3 months.ABOUBAKR ELNASHAR
  6. 6. 1/12/2020 6 1. DIMINISHED OVARIAN RESERVE One study  Sills et al, 2018, Gynecol Endocrinol.  4 women with diminished ovarian reserve  PRP  5 mL injected into each ovary under direct TVS guidance.  Improved ovarian function in all cases  Increase AMH  Decrease FSH or both  2 months after tt.  IVF after 78 ± 22 (range = 59-110) days  retrieval of 5.3 ± 1.3 MII oocytes.ABOUBAKR ELNASHAR 2. POOR RESPONDERS 2 studies Sfakianoudis et al, 2019, Gynecol Obstet Invest.  3 poor responders  failed IVF attempts, poor oocyte yield, and poor embryo quality.  PRP ovarian infusion  Within a 3-month interval  FSH decreased by 67.33%  AMH increased by 75.18%.  improved embryo quality.  Natural conception at 24 ws, an uncomplicated healthy pregnancy at 17 ws and a successful live birth. ABOUBAKR ELNASHAR
  7. 7. 1/12/2020 7 3. PREMATURE OVARIAN FAILURE Ovarian rejuvenation 2 studies Pantos et al., 2016, Annual Meeting of ESHRE  8 perimenopausal/ POF  PRP injected  successful ovarian rejuvenation 1–3 months after PRP tt.  All cases underwent natural IVF cycles: follicles of 15.20±2.05 mm in diameter,  ICSI& all resulting embryos were cryopreserved. ABOUBAKR ELNASHAR ABOUBAKR ELNASHAR Proposed mechanism of action for alteration of adult ovarian function by application of activated PRP (Sills & Wood, 2019)
  8. 8. 1/12/2020 8 ABOUBAKR ELNASHAR Proposed mechanism of action for alteration of adult ovarian function by application of activated PRP (Sills & Wood, 2019) PLT-derived growth factors trigger or enable differentiation of OSCs  Reduced FSH and/or  Increased AMH  consistent with improved or ‘re- potentiated’ ovarian function. ABOUBAKR ELNASHAR  The traditional dogma  Oocyte stores  Limited  non-renewable  No evidence for neo-oogenesis in adult monkey Stem Cells. (Yuan et al.,2013)  Existence of adult ovarian Germline SCs  an unlimited source of oocytes (Hanna et al; 2014)  potential roles in infertility TT&fertility preservation (Dunlop et al,2013)  Female mice lack adult germ-line stem cells Transformation of somatic cells into stem cell-like cells under specific in vitro conditions (Lee et al,2013)
  9. 9. 1/12/2020 9  Comment  Number of studies: Few  Number of patients: Few  Type of studies: all case series, or case report, No RCT  Journal of publication:  Cl Med  Gyn Endocr  Cell transplantation  Experimental ABOUBAKR ELNASHAR Indication No of patients Type of study 1. Thin endometrium  Chang et al.;2015, Int J Clin Exp Med.  Colombo et al.,2017,J Biol Regul Homeost Agents  Zadehmodarres et al., 2017, JBRA Assist Reprod  Tandulwadkar et al, 2017,J Hum Reprod Sci  Wang et al, 2018, J Cell Biochem  Kim et al, 2019, Front Endocrinol  Chang et al, 2019, Medicine  Li et al, 2017, ESHRE annual meeting  Eftekhar et al, 2018, Taiwan J Obstet Gynecol.  Nazari et al, 2019, Int J Reprod Biomed 5 8 10 68 20 22 60 42 40 30 Case series Case series Case series Case series Case series Case series Case series RCT RCT 102 RCT  Total 245 Intrauterine PRP 10 studies ABOUBAKR ELNASHAR
  10. 10. 1/12/2020 10 Intrauterine infusion procedure Using IU catheter Amount: 0.5-1 ml (Aghajanova et al, 2018)  0.7ml (Dieamant 2019 )  How many times: 2 or 3 times in the same cycle ABOUBAKR ELNASHAR  Timing:  D10 of HRT cycle& repeat after 72 h: if EnT still <7 mm (Chang et al.;2015, Li et al, 2017)  D11-12 of HRT cycle& repeat after 48 h (Nazari et al, 2019)  D13 of HRT cycle& repeat after 48 h (Eftechar et al, 2018)  ET  24 hr after final infusion (Farimani et al, 2017)  72 hr after the final infusion (Kim et al, 2019) ABOUBAKR ELNASHAR
  11. 11. 1/12/2020 11  Li et al, 2017: ESHRE annual meeting 2017: RCT PRP group 42 cycles Control group 51 cycles EnT(mm) 7.7±0.2 6.5±0.3 Cancellation rate (%) 19 41 IR (%) 28 12 CPR (%) 44 20  PRP for thin endometrium improved  Endometrium proliferation  Implantation rate  CPR ABOUBAKR ELNASHAR  Comment  Number of studies: 10  Number of patients: 245  Type of studies: all are case series, only 3 RCC (102 patients)  Results: promising  PRP may be effective in improving endometrial growth& possibly pregnancy outcomes in women with thin endometrium.  More RCT are required to confirm efficacy ABOUBAKR ELNASHAR
  12. 12. 1/12/2020 12 Indication No of patients Type of study 2. Repeated implantation failure  Farimani et al, 2017, Int J Reprod Biomed  Nazari et al., 2016, Int J Reprod Biomed  Mehrafza et al, 2019, J Rep Inf  Coksuer et al, 2019, Gynecol Endocrinol 1 20 60 34 Case report Case series Case series Case series Total 135 ABOUBAKR ELNASHAR  Nazari et al., 2016, Int J Reprod Biomed (Yazd)  20 with a history of RIF  younger than 40 years  BMI below 30 kg/m2.  16 (80%) CPR  PRP was effective in improving pregnancy outcomes in RIF. ABOUBAKR ELNASHAR
  13. 13. 1/12/2020 13 Indication No of patients Type of study 3. Chronic endometritis  Sfakianoudis et al, 2019, In Vivo 1 Case report 4. Asherman syndrome.  Aghajanova et al, 2018, Fert Ster. 7 RCT ABOUBAKR ELNASHAR  In RIF due to persistent CHRONIC ENDOMETRITIS (CE): (Sfakianoudis et al, 2019, In Vivo)  IU PRP& subsequent ET:  No signs of CE  Twin pregnancy.  PRP may be employed as a first-line treatment of CE, especially for patients who fail to respond to antibiotic. ABOUBAKR ELNASHAR
  14. 14. 1/12/2020 14 PRP in ASHERMAN SYNDROME (AS)  combined with standard surgical& medical tt  significant increase in EnT  a feasible& promising experimental tool in management of AS. ABOUBAKR ELNASHAR CONCLUSION  PRP  An innovative therapeutic modality  Affordable, simple, easily performed.  Intraovarian PRP  Diminished ovarian reserve  Poor ovarian response experimental  Premature ovarian failure ABOUBAKR ELNASHAR
  15. 15. 1/12/2020 15  Intrauterine PRP  Thin endometrium: promising & more RCT are required  RIF  CE experimental  AS ABOUBAKR ELNASHAR  There is a need for 1. Research on cellular& molecular level to improve our knowledge on PRP mode of action 2. Standardization of PRP 1. Preparation methods 2. Application methods 3. Well-designed, large RCT to confirm its efficacy &safety  Without strong, unbiased evidence, any intervention is a suspect until proven otherwise.ABOUBAKR ELNASHAR
  16. 16. 1/12/2020 16 You can get this lecture and 446 lecture from: 1.My scientific page on Face book: Aboubakr Elnashar Lectures. https://www.facebook.com/groups/2277448840913 51/ 2.Slide share web site 3. elnashar53@hotmail.com 4.My clinic: Althwara st, Mansura, Egypt ABOUBAKR ELNASHAR

×